A5086905802- Cholinesterase and Neurodegenerative Diseases
- Computational Drug Discovery Methods
- Alzheimer's disease research and treatments
- Medicinal Plants and Neuroprotection
- Synthesis and biological activity
- Parkinson's Disease Mechanisms and Treatments
- Neuroscience and Neuropharmacology Research
- Nanoparticle-Based Drug Delivery
- Epilepsy research and treatment
- RNA Interference and Gene Delivery
- Treatment of Major Depression
- Cancer, Hypoxia, and Metabolism
- Luminescence Properties of Advanced Materials
- Sirtuins and Resveratrol in Medicine
- Chemical Synthesis and Reactions
- Natural product bioactivities and synthesis
- Analytical Chemistry and Chromatography
- Diet and metabolism studies
- Chemical synthesis and alkaloids
- Metabolomics and Mass Spectrometry Studies
- Ammonia Synthesis and Nitrogen Reduction
- Electrochemical sensors and biosensors
- Catalytic Processes in Materials Science
- Drug Transport and Resistance Mechanisms
- Pharmacological Receptor Mechanisms and Effects
Ezhou Central Hospital
2025
North Sichuan Medical University
2023-2025
Sichuan University
1993-2021
Indiana University School of Medicine
1998
Indiana University
1998
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, but no drugs can cure this disease. Chalcones possess good antioxidant activity, anti-neuroinflammatory neuroprotective effects, inhibitory effects on Aβ aggregation, and disaggregation ability. Therefore, chalcones are ideal lead compounds, discovery of novel anti-AD agent-based necessary. Hydroxy groups aryl benzyl ether were introduced into chalcone scaffolds to obtain a series 2-hydroxyl-4-benzyloxy derivatives....
ABSTRACT Gliomas are one of the most prevalent types solid tumors in brain. Imbalances mitochondrial metabolism have been implicated pathological progression gliomas. Etomidate, an agonist γ‐aminobutyric acid type A (GABAA) receptor, is widely used clinical settings. In this study, we report a novel pharmacological function etomidate regulating glioma cancer cells. U87 tumor cells were treated with (0.5, 1.0, and 2.0 µg/mL) for 24 h. Quantitative real‐time PCR, western blot analysis,...
A novel series of chalcone-Vitamin E-donepezil hybrids was designed and developed based on multitarget-directed ligands (MTDLs) strategy for treating Alzheimer's disease (AD). The biological results revealed that compound 17f showed good AChE inhibitory potency (ratAChE IC50 = 0.41 µM; eeAChE 1.88 µM). Both the kinetic analysis docking study a mixed type inhibitor. also antioxidant (ORAC 3.3 eq), selective metal chelator huMAO-B inhibitor (IC50 8.8 Moreover, it remarkable inhibition self-...
To discover novel multifunctional agents for the treatment of Parkinson's disease, a series 2-(4-(benzyloxy)-5-(hydroxyl) phenyl) benzothiazole derivatives was designed, synthesized and evaluated. The results revealed that representative compound 3h possessed potent selective MAO-B inhibitory activity (IC50 = 0.062 µM), its mode competitive reversible. Additionally, also displayed excellent anti-oxidative effect (ORAC 2.27 Trolox equivalent), significant metal chelating ability appropriate...
Abstract A series of 2‐hydroxy‐4‐benzyloxylimine resveratrol derivatives was designed, synthesized and evaluated as multifunctional agents for the treatment Parkinson's disease. The results revealed that most possessed good activities. Among them, representative compound ( E )‐5‐[(4‐fluorobenzyl)oxy]‐2‐{[(4‐hydroxyphenyl)imino]methyl}phenol 7 h ) exhibited excellent MAO‐B inhibition (IC 50 =8.43×10 −3 μM) high antioxidant activity (ORAC=3.45 Trolox equivalent). Additionally, displayed metal...